Post-translational sumoylation, the covalent attachment of a small ubiquitin-like modifier (SUMO), regulates the functions of proteins engaged in diverse processes. Often associated with nuclear and perinuclear proteins, such as transcription factors, it is not known whether SUMO can conjugate to cell-surface receptors for growth factors to regulate their functions. Here we show that the type I transforming growth factor-β (TGF-β) receptor, TβRI, is sumoylated in response to TGF-β and that its sumoylation requires the kinase activities of both TβRI and the type II TGF-β receptor, TβRII. Sumoylation of TβRI enhances receptor function by facilitating the recruitment and phosphorylation of Smad3, consequently regulating TGF-β-induced transcription and growth inhibition. TβRI sumoylation modulates the dissemination of transformed cells in a mouse model of TβRI-stimulated metastasis. TβRI sumoylation therefore controls responsiveness to TGF-β, with implications for tumour progression. Sumoylation of cellsurface receptors may regulate other growth factor responses.
TGF-β signalling has key functions in cell growth, differentiation, apoptosis, development and tumorigenesis. The mechanisms that lead to receptor activation and gene expression responses to TGF-β are generally understood 1 . Binding of TGF-β to a complex of two type I and two type II kinase receptors, namely TβRI and TβRII, confers TβRI activation and consequent direct carboxy-terminal phosphorylation of Smad2 and Smad3 by TβRI. The activated Smads then associate with Smad4 and translocate into the nucleus to regulate transcription of target genes. TGF-β signalling is modulated by other signalling pathways and post-translational modifications. Indeed, the function of the Smad proteins is controlled by phosphorylation, acetylation, ubiquitylation and sumoylation 2, 3 . Less is known about the regulation of TGF-β receptors by posttranslational modification. Because the receptor complex is a central point for protein interactions, post-translational modifications could have key functions in the transduction of TGF-β signals. So far, phosphorylation and ubiquitylation have been shown to modify the receptors post-translationally [3] [4] [5] [6] [7] . Thus, recruitment of E3 ubiquitin ligases, including Smurfs, by the inhibitory Smad6 or Smad7 to the TβRII-TβRI complex can lead to TβRI ubiquitylation and consequent degradation. We now show that SUMO proteins, which primarily modify nuclear proteins and regulate their function, are conjugated to TβRI receptors in a regulated manner. TβRI sumoylation modulates the function of the TGF-β receptors and helps define the cellular responses to TGF-β.
ReSUlTS

The type I TGF-β receptor TβRI is sumoylated
To examine the sumoylation of TβRI or TβRII, we expressed Flag-tagged rat TβRI or TβRII with Myc-tagged SUMO-1. Cell lysate immunoprecipitations with anti-Flag antibodies, followed by western blotting, detected Myc-tagged, sumoylated TGF-β receptors. As shown in Fig. 1a , SUMO was conjugated to TβRI, but not TβRII, resulting in a shift of more than 20 kDa, similar to that of other sumoylated proteins, indicating that TβRI is post-translationally sumoylated in vivo. TβRI sumoylation was increased when the E2-conjugating enzyme Ubc9 was co-expressed with SUMO-1, suggesting that Ubc9 is involved in the sumoylation of TβRI (Fig. 1b) . Under conditions of Ubc9 overexpression and proportionally insufficient E3 SUMO ligase expression, up to three sumoylated TβRI forms were observed. Because only one SUMO-1 can be linked to a Lys residue, we assume that, under these conditions, the initial, site-specific sumoylation can confer additional TβRI sumoylation at other sites.
We next evaluated whether TβRI can be sumoylated in vitro. Immunopurified TβRI was incubated with SUMO-1, the E1 activating SUMO enzyme, Aos1/Uba2, and Ubc9 in the presence of ATP. Western blotting detected a band with a size that was compatible with the attachment of a SUMO-1 protein to TβRI and corresponded to the sumoylated TβRI in vivo. When the E1 or E2 enzyme, or SUMO-1, was absent, this band was not detected (Fig. 1c) . This result suggests that TβRI was sumoylated in vitro.
Immunoprecipitation of TβRI from Mv1Lu or MDA-231 cells, treated with or without TGF-β, and immunoblotting with antibodies against SUMO-1, revealed that endogenous TβRI was sumoylated and that TGF-β induced TβRI sumoylation (Fig. 1d) . These data indicate that receptor activation by TGF-β may induce sumoylation of TβRI.
We assessed whether other type I TGF-β family receptors could be sumoylated. Each type I receptor was expressed in the presence or absence of SUMO-1 and Ubc9, and sumoylation was analysed by immunoblotting. Whereas TβRI was sumoylated, other type I receptors were not (Fig. 1e) .
TβRI kinase activity and phosphorylation are required for sumoylation of the TβRI receptor
To further characterize whether activation of TβRI affects its sumoylation, as apparent by the TGF-β-induced TβRI sumoylation (Fig. 1d) , we compared the in vitro sumoylation efficacy of immunopurified wild-type TβRI and activated TβRI (caTβRI) with a Thr 202 to Asp mutation (Thr 202 in rat TβRI corresponds to Thr 204 in human TβRI), resulting in elevated kinase activity 8 . As shown in Fig. 2a , caTβRI was sumoylated much more efficiently than wild-type TβRI, suggesting that TβRI activation, which normally occurs by TβRII-mediated phosphorylation in response to TGF-β, facilitates sumoylation of the receptor.
Because the activated TβRI has elevated kinase activity and increased phosphorylation 8 , we examined whether increased TβRI sumoylation resulted from increased TβRI kinase activity or phosphorylation. In vitro sumoylation of wild-type TβRI or caTβRI was decreased in the presence of SB431542, a specific TβRI kinase inhibitor, although this was more easily detected with caTβRI (Fig. 2b) . These data suggested that the TβRI kinase regulates TβRI sumoylation. Because TβRI did not phosphorylate SUMO-1, the E1 enzyme (Aos/Uba2) and Ubc9 ( Supplementary Information, Fig. S1a ), these data suggested that TβRI autophosphorylation has a role in its sumoylation. To determine whether Anti-TβRI Anti-TβRI
TβRI-SUMO TβRI Figure 1 The type I TGF-β receptor TβRI is sumoylated. (a) TβRI, but not TβRII, is sumoylated. Lysates of COS cells, expressing Flag-tagged (F-) TβRI or TβRII and Myc-tagged (M-) SUMO-1, were subjected to immunoprecipitation (IP) with anti-Flag antibody, followed by western blotting (WB) with anti-Myc to detect sumoylated TGF-β receptors. (b) Increasing expression of Ubc9 enhances TβRI sumoylation. COS cells, expressing Flagtagged TβRI, Myc-tagged SUMO-1 and increasing levels of Ubc9, were lysed and subjected to immunoprecipitation, followed by western blotting with the indicated antibodies. TβRI phosphorylation regulates TβRI sumoylation, we removed the Ser/ Thr phosphorylation from TβRI by using lambda phosphatase before in vitro sumoylation. The absence or decrease of TβRI phosphorylation decreased the sumoylation of wild-type or activated TβRI (Fig. 2b) . This again was more easily detected with activated TβRI than with wild-type TβRI, as a result of the difference in sumoylation level. These results suggest that increased kinase activity together with increased phosphorylation contribute remarkably to the efficiency of TβRI sumoylation. TGF-β binding to TβRII results in stable complex formation of two TβRII and two TβRI receptors, in which TβRII phosphorylates the TβRI cytoplasmic domain and thereby activates the TβRI kinase 1 . The activated receptor complex permits autophosphorylation of the TβRII and TβRI dimers. To determine the roles of the TβRII and TβRI kinases in TβRI sumoylation, we used a cytoplasmic chimaera that fused the TβRI cytoplasmic domain to the TβRII cytoplasmic domain 9 . In this complex, the TβRII kinase activates the TβRI kinase without the need to add TGF-β. The receptor chimaera, expressed in the presence of SUMO and Ubc9, was sumoylated. Because TβRII is not sumoylated (Fig. 1a) , the sumoylation site is within the TβRI cytoplasmic domain. Inactivation of the TβRI kinase by Lys 230 to Arg mutation decreased the chimaera sumoylation (Fig. 2c) , which was consistent with the decreased TβRI sumoylation in the presence of SB431542 (Fig. 2b) . Similar inactivation of the TβRII kinase by Lys 277 to Arg mutation also decreased sumoylation of the chimaera in comparison with the wild-type, kinase-active version (Fig. 2c) . Because the TβRII cytoplasmic domain is not targeted for sumoylation, this result indicates that phosphorylation of the TβRI cytoplasmic domain by the TβRII kinase is important in the sumoylation of TβRI. Mutation of both kinase ATP-binding sites in the chimaera blocked sumoylation. The requirement for both receptor kinase activities for sumoylation was also studied in vitro. The efficacies of in vitro sumoylation of wild-type, TβRI kinase-defective, TβRII kinase-defective and TβRI/II kinase-defective chimaeras, immunopurified from transfected cells, were compared (Fig. 2d) . Inactivation of the kinase functions of TβRII or TβRI strongly decreased the sumoylation in vitro, whereas inactivation of both kinases abolished sumoylation of the chimaera (Fig. 2d) .
These observations indicate that the kinase activities of both TβRI and TβRII, and the consequent phosphorylation of TβRI, are required for efficient TGF-β-induced sumoylation of TβRI in the receptor complex. This is consistent with the TGF-β-induced phosphorylation and consequent activation of TβRI by TβRII (Fig. 2e) .
The TβRI receptor is sumoylated on lys 389
Sumoylation often occurs on a lysine residue (K) within a consensus sequence ΨKx(D/E), in which Ψ represents a large hydrophobic residue 10 . Because this consensus sequence is absent from the amino-acid sequence of TβRI, each of the 20 lysine residues in the cytoplasmic domain was singly replaced by arginine, and the effect of each mutation on TβRI sumoylation was tested. Lysates of cells co-expressing each Flag-tagged lysine mutant of TβRI with SUMO-1 and Ubc9 were subjected to immunoprecipitation with anti-Flag antibody, followed by western blotting. TβRI was not sumoylated when Lys 389 was replaced by arginine, whereas replacements of other lysine residues by arginine did not affect the sumoylation of TβRI (Fig. 3a , and data not shown), indicating that Lys 389 is a major site for TβRI sumoylation. The Lys 389 mutation also affected in vitro sumoylation, because no sumoylated TβRI was detected when Lys 389 was replaced by arginine (Fig. 3b) . These results indicate that Lys 389 is the only residue targeted for sumoylation.
The proposed structure of the TβRI cytoplasmic domain (Fig. 3c ) predicts that Lys 389 is located in the hinge between the αEF helix and the αF helix, and is exposed at the surface of the C lobe of the kinase domain. The sumoylation site faces the same orientation as the GS region, which is phosphorylated by TβRII on the binding of TGF-β, and the L45 loop, which specifies the interaction with Smad, although in a separate protein domain. The GS region and L45 loop, both located in the N lobe, interact with the Smad for phosphorylation by TβRI. The exposure of Lys 389 at the protein surface predicts that conjugation with SUMO strongly affects the cytosolic surface of TβRI and may regulate the binding of Smad to the L45 loop and GS domain of TβRI, and interactions of additional proteins with the receptor complex.
Sequence comparisons (Fig. 3d) show that Lys 389 is not conserved in other TGF-β-family type I receptors, with the exception of the activin receptor ActRIB/ALK-4. This is consistent with the absence of sumoylation of these type I receptors in vivo (Fig. 1e) . The lack of ActRIB/ALK-4 sumoylation suggests that other determinants besides the target lysine are needed for sumoylation of TβRI. It is unlikely that this is due to the serine versus threonine difference, four residues preceding the sumoylated lysine residue in TβRI compared with ActRIB/ALK-4 ( Fig. 3d) , because S385T replacement did not affect the in vitro sumoylation of TβRI ( Supplementary Information, Fig. S1b ).
TβRI sumoylation regulates Smad interaction and activation
To evaluate whether sumoylation of the exposed Lys 389 affects Smad activation, we examined the interaction of Smad3 with caTβRI. Because this interaction is hard to detect by immunoprecipitation, probably as a result of its low affinity and transient nature, we examined the interaction of the Smad3D407E mutant with caTβRI. The D407E mutation in the MH2 domain was identified in Smad2 in colorectal carcinoma, and affects the interaction of Smad with TβRI and heteromerization with Smad4 (ref. 11). Increased caTβRI sumoylation by co-expressing Ubc9 and SUMO-1 enhanced the interaction of TβRI with Smad3D407E. In contrast, coexpression of SUMO and Ubc9 did not enhance the interaction of Smad3D407E with caTβRI carrying the sumoylation-resistant 
T g f b r 1 -/-(+ K 3 8 9 R + R a s ) K389R mutation (Fig. 4a) . We also incubated immobilized glutathione S-transferase (GST)-Smad3D407E with a mixture of sumoylated and unsumoylated TβRI. Western blotting of purified GST-Smad3-TβRI complexes showed preferential binding of Smad3 to sumoylated TβRI, in comparison with unsumoylated TβRI, even though the latter was in large excess (Fig. 4b) . This result, together with the data in Fig. 4a , indicates that sumoylation of TβRI enhances Smad3 recruitment and suggests that TβRI sumoylation enhances Smad activation.
Because TβRI phosphorylates Smad2 and Smad3 after the binding of TGF-β, we investigated whether sumoylation of activated TβRI affects Smad3 phosphorylation. TβRI-defective mouse embryonic fibroblasts (MEFs) derived from Tgfbr1 −/− mice 12 were retrovirally infected to express wild-type TβRI or sumoylation-resistant K389R TβRI. Stably selected cell populations, expressing either TβRI form at equal levels (Fig. 4c) , showed equivalent cell-surface levels of wild-type or mutant TβRI (Fig. 4d) , suggesting that the K389R mutation did not affect cellsurface transport or stability of TβRI. K389R TβRI also showed a similar phosphorylation level to that of wild-type TβRI, resulting primarily from the TβRI kinase activity, because SB431542 abolished this phosphorylation (Fig. 4e) . Fractionation of cell lysates did not reveal differences in subcellular compartmentalization of wild-type versus mutant TβRI ( Supplementary Information, Fig. S1c ). We then compared wild-type and K389R TβRI for their ability to phosphorylate Smad3 in response to TGF-β. In fibroblasts expressing wild-type TβRI, TGF-β induced Smad3 phosphorylation within 15 min, whereas, in cells expressing K389R TβRI, the Smad3 phosphorylation kinetics in response to TGF-β was slower, with first detection at 30 min. Furthermore, the overall level of Smad3 activation was lower in cells expressing K389R TβRI than in cells expressing wild-type TβRI (Fig. 4f) . Similar results were seen with TGF-β-induced activation of Smad2 (Fig. 4g) . Replacement of Lys 393 in ActRIB/ALK-4, which is not sumoylated and corresponds to Lys 389 in TβRI, with arginine did not affect Smad3 activation ( Supplementary  Information, Fig. S1d) .
The differences in level and kinetics of Smad2 and Smad3 phosphorylation by wild-type versus K389R TβRI, together with the results of the interaction of Smad3 with TβRI, suggest that TβRI sumoylation enhances the Smad interaction with TβRI, allowing more efficient phosphorylation and activation of Smad2/3 in response to TGF-β.
TβRI sumoylation regulates functional responses to TGF-β Using Tgfbr1
−/− fibroblasts ectopically expressing wild-type or K389R TβRI, we characterized the effect of TβRI sumoylation on Smadmediated transcription; that is, the functional consequence of Smad activation. We used a reporter in which tandem Smad-binding sites control luciferase transcription. Cells expressing K389R TβRI showed decreased transcription from the Smad3-responsive promoter compared with cells expressing wild-type TβRI (Fig. 4h) . We also compared the endogenous expression of the TGF-β-responsive Smad7 gene by reverse transcriptase polymerase chain reaction (RT-PCR). Cells expressing K389R TβRI showed decreased expression of Smad7 messenger RNA in response to TGF-β, compared with cells expressing wild-type TβRI (Fig. 4i) . Similar results were obtained with two additional populations of Tgfbr1 −/− fibroblasts ectopically expressing TβRI or K389R TβRI at similar levels ( Supplementary Information, Fig. S2 ). These results suggest that TβRI sumoylation defines the TGF-β-induced transcriptional regulation.
We also examined the contribution of TβRI sumoylation to the antiproliferative response to TGF-β. We seeded the fibroblasts expressing wild-type or K389R TβRI in parallel with the parental Tgfbr1 −/− cells as control cells, and determined the proliferative response after adding TGF-β. Cells lacking TβRI were not affected in their proliferation by TGF-β, whereas those expressing wild-type TβRI responded with decreased proliferation, as assessed by cell number (Fig. 4j) . In contrast with wild-type TβRI, cells expressing K389R TβRI showed a decreased growth inhibitory response to TGF-β. This result suggests that sumoylation regulates the TβRI-mediated antiproliferative response to TGF-β and renders the cells more responsive to TGF-β.
TβRI sumoylation enhances invasion and metastasis of Rastransformed cells
Because autocrine TGF-β signalling regulates cancer progression 13, 14 we postulated that resistance to sumoylation, while suppressing TGF-β growth inhibitory activities, affects tumour progression. To address this issue, the Tgfbr1 −/− fibroblasts, carrying a control empty vector or ectopically expressing wild-type or K389R TβRI at similar levels, were transduced with a control vector or a vector expressing activated Ha-Ras(Leu 61) to generate tumorigenic cell populations. Mutant Ras was expressed and activated extracellular signal-regulated kinase (ERK) MAP kinase to similar extents in all three Ras-transformed cell populations (Fig. 5a ). Cells expressing activated Ras had a transformed phenotype, which was apparent from the altered cell morphology and loss of contact inhibition (data not shown).
We examined the invasion of the Ras-transformed cells by using a modified Boyden chamber assay in which cells migrate through Matrigel towards serum. Ras-transformed Tgfbr1 −/− cells ectopically expressing wild-type TβRI showed a higher invasion activity than Rastransformed Tgfbr1 −/− cells lacking TβRI (Fig. 5b) , indicating that the invasive capacity of Ras-transformed MEFs depends on TβRI signalling. Ras-transformed Tgfbr1 −/− MEFs expressing K389R TβRI were less invasive than cells expressing wild-type TβRI, indicating that, in this system, lack of TβRI sumoylation impairs the TβRI-dependent invasion of transformed cells (Fig. 5b, c) . These observations are consistent with the role of sumoylation of TβRI in TGF-β-induced gene expression and growth inhibition (Fig. 4h-j) .
Metastasis is a complex process, requiring cell growth, migration, invasion, intravasation and extravasation, and cell survival in the circulatory system and at the metastatic site. Using a mouse tail-vein injection model, autocrine TGF-β signalling was shown to enhance the ability of tumour cells to establish metastatic nodules within the lung 15, 16 . To determine the roles of TβRI and sumoylation of TβRI in the formation of metastatic nodules in this model, we compared the ability of the Tgfbr1 −/− MEF derivatives to colonize the lung. Colonization of the lungs by MEFs was fully dependent on expression of activated Ha-Ras ( Fig. 5d, e ; data not shown). Ras-transformed Tgfbr1 −/− cells gave rise to only few very small lung tumour nodules (Fig. 5d, e) . Tumour cells were proliferative with a high incidence of apoptosis ( Supplementary Information, Fig. S3h ). The tumours were morphologically heterogeneous, and large cells with massive nuclei were indicative of chromosomal instability ( Supplementary  Information, Fig. S3e) . Remarkably, Ras-transformed Tgfbr1 −/− cells ectopically expressing wild-type or K389R TβRI developed numerous large metastatic nodules (Fig. 5d, e) . MEFs expressing sumoylationdefective TβRI gave rise to fewer tumour nodules than cells expressing the wild-type receptor (Fig. 5e ). These nodules were generally smaller than those from wild-type MEFs expressing TβRI (Fig. 5d , and data not shown), although their histological appearance (Fig. 5d ) and proliferative rates ( Supplementary Information, Fig. S3a ) were similar. These results suggest that, in this model of TGF-β-mediated metastasis, TβRI sumoylation contributes to tumour progression by enhancing tumour cell extravasation, survival and/or growth at the metastatic site.
The Ser385Tyr mutation of TβRI, implicated in metastatic cancer, confers sumoylation resistance Mutations in TGF-β signalling mediators, including TGFBR1, have been associated with human cancers 13 . Among these, a missense mutation, S387Y, in TGFBR1 was enriched in breast and head-and-neck cancer metastases, in comparison with corresponding primary tumours 17, 18 . This mutation confers diminished TGF-β signalling and is the only mutation in TGFBR1 or TGFBR2 known to associate specifically with tumour metastases 17 . Because the corresponding residue in rat TβRI, namely Ser 385, localizes close to the Lys 389 sumoylation site of TβRI (Fig. 6a) , we examined whether rat S385Y TβRI was sumoylated. In contrast with wild-type TβRI, this mutant was not sumoylated in cells overexpressing SUMO-1 and Ubc9 (Fig. 6b) . In vitro, replacement of Ser 385 with Tyr (Fig. 6c) or Ala (Fig. 6d) also strongly decreased sumoylation. In contrast, replacement of Ser 385 with Thr, which may, similarly to Ser, be targeted for phosphorylation by Ser/Thr kinases, did not affect sumoylation ( Supplementary Information, Fig. S1b ). These results indicate that this single amino-acid substitution prevents TβRI sumoylation.
We examined whether the S385Y mutation decreased the responsiveness to TGF-β, as observed with the sumoylation-defective K389R TβRI (Fig. 4) . Using the Smad3-responsive reporter of Fig. 4h , cells expressing S385Y TβRI responded to TGF-β with a lower level of transcription than cells expressing wild-type TβRI, but a higher level than cells expressing K389R TβRI (Fig. 6e) , indicating that the decreased TGF-β responsiveness associated with S385Y TβRI correlates with impaired TβRI sumoylation. We also evaluated the S385Y TβRI mutation in the lung colonization tumour model. Ras-transformed MEFs expressing S385Y TβRI formed fewer and smaller metastatic nodules than cells expressing wild-type TβRI (Fig. 6f, g ). Although this difference in tumour nodule formation is qualitatively comparable to that of K389R TβRI cells, the efficiency of metastatic nodule formation was more impaired in S385Y TβRI cells than in K389R TβRI cells. This quantitative difference between cells expressing K389R TβRI or S385Y TβRI, when compared with their differential activities in transcription assays, raises the possibility that the impaired TβRI sumoylation resulting from the S385Y mutation may be complemented with an additional defect of relevance to cancer progression.
DIScUSSIOn
Here we provide evidence that a cell-surface polypeptide growth factor receptor is modified by sumoylation in a regulated, ligand-dependent manner. Conjugation of SUMO to TβRI depends on TβRI activation by phosphorylation, which in turn is induced by the binding of TGF-β to the TβRII-TβRI complex. TGF-β receptor sumoylation enhances the recruitment and activation of Smad3, and consequently regulates TGF-β responses.
Little is known about the sumoylation of transmembrane proteins and how this affects their function. The ion channel proteins K2P1 and Kv1.5 are sumoylated, and this modification regulates their inactivation 19, 20 . Sumoylation of the kainate receptor subunit GluR6 is increased in response to kainate and enhances endocytosis, resulting in a negative effect on synaptic transmission 21 . This raises the possibility that TβRI sumoylation affects the internalization, recycling and/or stability of receptors.
Interplay between different modifications provides a mechanism for regulating protein function. For example, phosphorylation, acetylation, methylation and ubiquitylation of histone H3 and H4 amino-terminal sequences affect each other to control gene expression 22 . Stress-induced N-terminal phosphorylation of p53 regulates its C-terminal acetylation 23 . In addition, Smad7 acetylation inhibits its ubiquitylation 24 . Here we show interplay between phosphorylation and sumoylation in regulating TβRI function. Thus, TGF-β-induced phosphorylation of TβRI by itself and TβRII is required for the sumoylation of TβRI to regulate its function. Phosphorylation-dependent sumoylation has been observed in transcription regulators, such as heat-shock factors, GATA-1 and MEF-2, and was shown to involve a ΨKxExxSP motif 25 . Within this motif, serine phosphorylation was suggested to contribute to sumoylation of lysine. Although TβRI lacks this motif, the dependence of TβRI sumoylation on phosphorylation is consistent with the requirements of the kinase activities of the receptor complex, and consequent TβRI phosphorylation, for TβRI sumoylation. How TβRI phosphorylation augments sumoylation remains to be determined.
TβRI sumoylation provides a new mechanism for the functional regulation of TGF-β responses. By regulating Smad activation and downstream transcription responses, TβRI sumoylation may elaborate the TGF-β responses that drive cancer progression. Indeed, sumoylation is thought to be important in tumorigenesis because some oncogene proteins and tumour suppressors [26] [27] [28] [29] are sumoylated. In addition, sumoylation of the reptin chromatin complex regulates the KAI1 metastasis suppressor gene and the invasive activity of cancer cells 30 . We here provide independent data to link sumoylation with tumour progression. Increased TGF-β1 expression by tumour cells and their microenvironment, and increased TGF-β signalling within tumour cells, are thought to be important factors in cancer progression 16, 18 . In a model of TGF-β-dependent metastasis of cancer cells to the lung, TβRI sumoylation enhanced tumorigenesis.
The proposed association of a sumoylation-resistant TβRI mutant with breast cancer metastasis 14 seems at odds with our in vivo results with Ras-transformed Tgfbr1 −/− fibroblasts. Differences in cellular origin of the tumours (highly malignant epithelial cells versus diploid embryonic fibroblasts 31 ) and the use of an immune-incompetent mouse model that addresses only a few components of the metastatic process may explain this discrepancy. In comparison with MEFs, human metastatic tumours bear multiple mutations 32 ; these tumours have elevated levels of sumoylating enzymes and diminished levels of desumoylating enzymes 30 . Thus, there may be a metastatic advantage to mutating the TβRI sumoylation site to prevent overactivation of the receptor. Retention of functional TGF-β receptors is advantageous to the spread of metastatic tumours 15 ; thus, human tumours with homozygous deletion of TGFBR1 or TGFBR2 are rare 13, 14 and present a better prognosis for patient survival 13, 14 . Mutation of the sumoylation site might more subtly alter TβRI activity, modulating a mechanism that contributes to metastasis while retaining enough TβRI activity for the intravasation and extravasation of tumour cells. Overall, though, along with a previous report 30 , our data suggest a connection between sumoylation and cancer progression.
MeTHODS
Plasmids. The expression plasmids for N-terminally Flag-tagged or Myc-tagged SUMO-1, or Ubc9 or C-terminally Flag-tagged TβRI have been described 33, 34 . The expression plasmid for the Flag-tagged TβRII-TβRI cytoplasmic chimaera has also been described 9 . Site-directed mutagenesis with the QuikChange kit (Stratagene, La Jolla, CA) generated plasmids encoding C-terminally Flag-tagged TβRI or TβRII-TβRI cytoplasmic chimaeras with amino-acid substitutions, and mutations were confirmed by DNA sequencing. To generate retroviral vectors expressing Flag-tagged TβRI, the coding region was inserted into the HpaI site of LNCX 35 . The retroviral vector pBABE-H-Ras(Leu 61)-IRES-Puro 36 was provided by R. Davis (University of Massachusetts Medical School, Worcester, MA). The expression plamid for Myc-tagged Smad3(D407E) 11 was provided by K. Miyazono (University of Tokyo, Tokyo, Japan). Expression plasmids for haemagglutinin (HA)-tagged ALK-1, ALK-3 or ALK-6 were generated by subcloning the coding regions from pcDNA3-HA-ALK1, pcDNA3-HA-ALK3 and pcDNA3-HA-ALK6 (refs 37, 38), provided by P. ten Dijke (University of Leiden, Leiden, The Netherlands), into the EcoRI/XhoI site of pRK5. A plasmid encoding Flag-tagged ALK-2 was made by inserting the coding region from pRK5-Myc-ALK2 into the EcoRI/SalI site of pXFIF 39 . To generate a plasmid encoding Flag-tagged ALK-4, the coding region from pcDNA1-hALK4 (ref. ) for 16 h. Cell extracts were prepared and assayed for luciferase activity as described 42 . Luciferase activities were normalized to β-galactosidase activity from a co-transfected β-galactosidase plasmid.
Immunoprecipitations and immunoblotting. COS or 293T cells were harvested 48 h after transfection and lysed by brief sonication in lysis buffer (25 mM TrisHCl pH 7.5, 150 mM NaCl, 1% TritonX-100, 10% glycerol, and protease inhibitor cocktail). Lysates were subjected to immunoprecipitation with anti-Flag M2 agarose (Sigma-Aldrich). Immune complexes were washed three times with lysis buffer and subjected to western blotting with anti-Flag or anti-Myc antibodies. To detect sumoylation of endogenous TβRI, Mv1Lu or MDA-231 cells were cultured for 3 h in DMEM with 0.2% FBS with or without TGF-β (10 ng ml GST adsorption assays. Immunopurified Flag-tagged TβRI was subjected to in vitro sumoylation. The mixture of sumoylated and unsumoylated TβRI was incubated with immobilized GST-Smad3(D407E) in 50 mM Tris-HCl pH 7.5, 120 mM NaCl, 0.1% Nonidet P40, 10% glycerol and protease inhibitor cocktail. After pull-down, precipitates were subjected to SDS-PAGE followed by western blotting with anti-Flag antibody to detect TβRI.
Generation of stable cell lines. Tgfbr1
−/− cells were infected with the LNCX-based retroviral vector expressing Flag-tagged wild-type or K389R TβRI, and stably infected cell populations were generated as described 43 . The expression levels of TβRI were assessed by western blotting with anti-Flag antibody.
To generate Ras-transformed cells, Tgfbr1 −/− cell populations with an empty vector or expressing Flag-tagged wild-type or K389R TβRI were transduced with the retroviral vector pBABE-H-Ras(Leu 61)-IRES-Puro or control vector pBABE-Puro, and selected with 2 µg ml −1 puromycin. The expression levels of H-Ras(Leu 61) were examined by western blotting with anti-c-H-Ras antibody (Calbiochem, San Diego, CA), and phosphorylated ERK1/2 was detected by western blotting with anti-phospho-ERK1/2 antibody (Cell Signaling Technologies).
In vitro kinase assays. Immunopurified receptors were incubated at 30 °C for 30 min in 10 mM HEPES-KOH pH 7.5, 5 mM MgCl 2 and 5 mM CaCl 2 with or without 5 µM TβRI kinase inhibitor SB431542. The reaction mixture was subjected to SDS-PAGE, followed by autoradiography.
Cell-surface TGF-β receptor biotinylation and precipitation. Tgfbr1
−/− cells expressing wild-type or K389R TβRI, or transfected with an empty vector, were grown to confluence and labelled with sulpho-N-hydroxysuccinimido biotin (Pierce) at 4 °C for 2 h. Cells were washed with 100 mM glyine and lysed by brief sonication in 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton cX-100, 10% glycerol, and protease inhibitor cocktail. Biotinylated cell-surface proteins were precipitated with avidin-immobilized beads (Pierce) and subjected to western blotting with anti-Flag antibody to detect cell-surface TβRI.
TGF-β response analyses. To evaluate Smad3 phosphorylation, Tgfbr1
−/− cells expressing wild-type or K389R TβRI were treated without or with 2.5 ng ml To perform the cell growth inhibition assay, 5 × 10 4 Tgfbr1 −/− cells expressing wild-type or K389R TβRI or having an empty vector were grown for 3 days in DMEM with 10% FBS without or with TGF-β, and cell numbers were counted with a haemocytometer.
To quantify Smad7 mRNA expression, Tgfbr1 −/− cells expressing Flag-tagged wild-type or K389R TβRI were treated with or without TGF-β (2.5 ng ml −1 ) for 4 h. RNA was isolated with RNeasy kit (Qiagen) and used as a template for reverse transcriptase. The Smad7 mRNA was quantified by real-time PCR with cyber-green (Invitrogen), and normalized against RPL19 mRNA. The primer sequences were as follows: Smad7, 5´-TCTGGACAGTCTGCAGTTGG-3´ (forward) and 5´-TCCTGCTGTGCAAAGTGTTC-3´ (reverse); RPL19, 5´-GGAAGAGGAAGGGTACTGCC-3´ (forward) and 5´-GGATTCCCGGTATCTCCTGAG-3´ (reverse).
In vitro invasion assay. In vitro invasion assays were performed with Biocoat Matrigel Invasion chambers (BD Biosciences). Cells (2.5 × 10 4 ) were seeded into the upper insert of the chamber and incubated for 24 h, allowing invasion through Matrigel towards 10% serum. The invaded cells were fixed with 96% ethanol and stained with 0.05% crystal violet.
Tumour formation. To perform lung tumour formation assays, 5 × 10 5 cells were injected into the tail vein of eight-week-old nude mice 36 . Three weeks after injection, the mice were labelled by intraperitoneal injection of 100 mg kg −1 5-bromo-2-deoxyuridine (BrdU). At 1 h after injection of BrdU, the mice were killed, lung tumour nodules were counted, and lungs were fixed in 4% paraformaldehyde and processed for histological analysis of paraffin-embedded tissue sections.
Immunostaining for BrdU was performed with biotin-conjugated mouse antiBrdU antibody (Alexis Biochemicals); detection was with the Vectastain Elite ABC kit detection system (Vector Laboratories). Panel e is a higher magnification of b (x20), showing the enlarged cells with meganuclei (white arrow) and apoptic bodies (green arrow), characteristic of these tumor nodules. Panels f and g are higher magnifications (x20) of boxes I and II in panel c. Panels h, i and j show BrdU staining of sections adjacent to those in panels e-g. Tumors embedded within the lung consisted of densely packed and proliferative epithelial-like cells (3c [Box 1], 3d, f, i), whereas more superficial nodules also possessed loose mesenchymal cells protruding into the pleural cavity, and had scarce BrdU-positive nuclei (Fig. 3c [Box II], 3g, j) . 
